🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10 results for “mirikizumab” Clear

  1. Mirikizumab

    Eli Lilly and Company

    Ulcerative Colitis

    phase 3 small molecule active

    2 trials

  2. Mirikizumab SC

    Eli Lilly and Company

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  3. Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  4. Mirikizumab, Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  5. Mirikizumab, Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  6. Mirikizumab, Tirzepatide, to match Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  7. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Mirikizumab, to match Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 small molecule active

    1 trial

  8. Eltrekibart, 0.9% sodium chloride, Mirikizumab, Mirikizumab, Placebo for LY3074828 SC Injection, 1mL Prefilled Syringe

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  9. Mirikizumab - Intravenous (IV)

    Eli Lilly and Company

    Colitis, Ulcerative

    phase 2 small molecule active

    1 trial

  10. Placebo to match LY, Mirikizumab, Placebo to Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources